Shares of Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $5.00.
Several equities analysts have issued reports on MBOT shares. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a research report on Wednesday, October 21st. UBS Group set a $2.50 price objective on shares of Microbot Medical in a research note on Friday, October 23rd. B. Riley Financial assumed coverage on Microbot Medical in a research note on Friday, September 11th. They issued a “buy” rating and a $4.00 price target for the company. Citigroup reiterated a “market outperform” rating on shares of Microbot Medical in a research report on Tuesday. Finally, Zacks Research cut Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th.
Read Our Latest Stock Report on MBOT
Microbot Medical Price Performance
Shares of NASDAQ MBOT opened at $0.72 on Thursday. Microbot Medical has a 12 month low of $0.52 and a 12 month high of $2.85. The stock has a 50-day moving average price of $1.12 and a two-hundred day moving average price of $1.78.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.01 million. Equities analysts forecast that Microbot Medical will post -0.30 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its position in shares of Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 71,560 shares during the period. Cetera Investment Advisers increased its holdings in shares of Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 13,099 shares during the period. CTC Alternative Strategies Ltd. purchased a new stake in shares of Microbot Medical in the first quarter worth $28,000. Finally, Private Advisor Group LLC purchased a new position in Microbot Medical during the first quarter worth about $54,000. 16.30% of the stock is currently owned by hedge funds and other institutional investors.
About Microbot Medical
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
Recommended Stories
- Five stocks we like better than Microbot Medical
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
